← All reportsView on Symbol
CPRX

CPRX

Watchlist

Catalyst Pharmaceuticals, Inc.

Healthcare · NASDAQ

$3.9B mkt cap

Brief updated Today

Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncom

Decifer Research·AI synthesis

CPRX driven by biotech growth

Catalyst Pharmaceuticals operates in the biotechnology sector with a high gross margin of 8232.0%. The company's revenue growth of 5.6% year-over-year and net margin of 3708.0% are notable. The conviction score of 27/100 indicates a cautious outlook, despite an analyst consensus rating of BUY. This contrast makes the setup interesting, with a DCF intrinsic value of $137,

Why now

The current macro context, with a focus on healthcare and biotech, makes this a crucial moment to assess CPRX's prospects. The company's unique financial profile, with exceptionally high margins, warrants attention amidst the broader market dynamics,

Key risks

Valuation risk is a concern, given the high P/E ratio of 17.4x. Execution risk also exists, as the company's ability to maintain its high margins and revenue growth is uncertain. Additionally, competitive risk in the biotechnology sector poses a threat to CPRX's market position,

What to watch

The company's future revenue growth and margin maintenance will be key indicators to confirm or deny the thesis. Investors should monitor CPRX's performance over the next few quarters, particularly its ability to sustain a high net margin and deliver on its growth prospects,

34Watchlist Conviction
macro
5/25
analyst
15/38
momentum
5/20
forward catalyst
0/15
valuation
14/23
highs
3/12
news catalyst
0/12
options flow
0/12
peer network
-5/8
counter thesis
0/3
Key financials
Revenue growth (YoY)563.0%
Gross margin8232.0%
Operating margin4483.0%
Net margin3708.0%
P/E ratio17.4x
Return on equity2365.0%
FCF yield540.0%
Debt / equity0.0x
EV / sales5.2x
Valuation
Analyst consensusBUY
DCF fair value$137
Next EPS estimate$0.49
Theme exposure
Healthcare, Biotech & DevicesDirect

Catalyst Pharmaceuticals, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Macro context

Trump Criticized Biden for Draining America’s Oil Reserves. They’re Now at a 43-Year Low Amidst a Middle East War.

US Strategic Petroleum Reserve levels have fallen to a 43-year low, reducing the government's capacity to buffer oil price shocks at a time of active Middle East conflict. This structural vulnerability in US energy policy raises concerns about energy security and the ability to respond to supply disruptions.

6d ago

Trump Criticized Biden for Draining America’s Oil Reserves. They’re Now at a 43-Year Low Amidst a Middle East War.

US Strategic Petroleum Reserve levels have fallen to a 43-year low amid an active Middle East conflict, reducing America's buffer capacity against oil supply disruptions. This constrains the US government's ability to intervene in energy markets during a period of elevated geopolitical risk.

6d ago

U.S. Central Command Posts On X "At 5:45 p.m. ET today, Islamic Revolutionary Guard Corps forces launched multiple ballistic missiles from Iran in an attempted surprise attack on U.S. forces based in the Middle East. All Iranian missiles were successfully intercepted. U.S. forces remain vigilant and at a high state of readiness."

Iranian IRGC forces launched a ballistic missile attack on U.S. military positions in the Middle East, which was fully intercepted according to U.S. Central Command. This represents a direct state-on-state military strike against U.S. forces, dramatically escalating regional tensions and raising the risk of broader conflict.

6d ago

Equities Lower Intraday Ahead of Fed Decision, Major Tech Earnings

The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings reports, is poised to influence the overall economic outlook.

5d ago

Analyst intelligence
12 Buy4 Hold0 Sell
Earnings intelligence

Earnings surprises

-18.8%

2026-05

+61.9%

2026-02

+33.3%

2025-11

+17.2%

2025-08

+28.3%

2025-05

Generated Tue, 04 Aug 2026 06:47:59 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.